Studies using MGMT methylation as a prognostic and predictive biomarker of GBM were reported before, in which a statistically significant difference in the level of DNA methylation from 5-methylcytosine content was found when compared with normal tissue and benign neoplasms [133,134]. The gene discussed is MGMT; the disease is glioblastoma.